NASDAQ: VIGL
Vigil Neuroscience Inc Stock

$2.76+0.05 (+1.85%)
Updated Feb 14, 2025
VIGL Price
$2.76
Fair Value Price
$0.99
Market Cap
$112.83M
52 Week Low
$1.49
52 Week High
$6.06
P/E
-1.34x
P/B
1.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$82.60M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.48
Operating Cash Flow
-$49M
Beta
0.97
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

VIGL Overview

Vigil Neuroscience Incorporated is a microglia-focused company that develops disease-modifying therapeutics for rare and common neurodegenerative diseases. Its lead product candidate is VGL101 is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company was incorporated in 2020 and is headquartered in Cambridge, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine VIGL's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

D
Value
C
Growth
C
Momentum
C
Sentiment
F
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
VIGL
Ranked
#483 of 561

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important VIGL news, forecast changes, insider trades & much more!

VIGL News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VIGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VIGL ($2.76) is overvalued by 180.13% relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VIGL ($2.76) is not significantly undervalued (180.13%) relative to our estimate of its Fair Value price of $0.99 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VIGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VIGL due diligence checks available for Premium users.

Valuation

VIGL fair value

Fair Value of VIGL stock based on Discounted Cash Flow (DCF)

Price
$2.76
Fair Value
$0.99
Overvalued by
180.13%
VIGL ($2.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VIGL ($2.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VIGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VIGL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-1.34x
Industry
-169.22x
Market
37.92x

VIGL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.27x
Industry
4.77x
VIGL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VIGL's financial health

Profit margin

Revenue
$0.0
Net Income
-$19.3M
Profit Margin
0%
VIGL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$131.3M
Liabilities
$42.7M
Debt to equity
0.48
VIGL's short-term assets ($113.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VIGL's short-term assets ($113.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VIGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$4.3M
Investing
-$16.6M
Financing
$19.9M
VIGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VIGL vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
VIGLD$112.83M+1.85%-1.34x1.27x
COYAC$113.61M-0.58%-10.46x3.55x
EDITF$113.92M+12.20%-0.54x0.65x
TCRXD$109.41M+0.49%-2.14x0.48x
SAVAC$116.43M+1.68%-6.54x0.70x

Vigil Neuroscience Stock FAQ

What is Vigil Neuroscience's quote symbol?

(NASDAQ: VIGL) Vigil Neuroscience trades on the NASDAQ under the ticker symbol VIGL. Vigil Neuroscience stock quotes can also be displayed as NASDAQ: VIGL.

If you're new to stock investing, here's how to buy Vigil Neuroscience stock.

What is the 52 week high and low for Vigil Neuroscience (NASDAQ: VIGL)?

(NASDAQ: VIGL) Vigil Neuroscience's 52-week high was $6.06, and its 52-week low was $1.49. It is currently -54.46% from its 52-week high and 85.23% from its 52-week low.

How much is Vigil Neuroscience stock worth today?

(NASDAQ: VIGL) Vigil Neuroscience currently has 40,879,485 outstanding shares. With Vigil Neuroscience stock trading at $2.76 per share, the total value of Vigil Neuroscience stock (market capitalization) is $112.83M.

Vigil Neuroscience stock was originally listed at a price of $12.65 in Jan 7, 2022. If you had invested in Vigil Neuroscience stock at $12.65, your return over the last 3 years would have been -78.18%, for an annualized return of -39.8% (not including any dividends or dividend reinvestments).

How much is Vigil Neuroscience's stock price per share?

(NASDAQ: VIGL) Vigil Neuroscience stock price per share is $2.76 today (as of Feb 14, 2025).

What is Vigil Neuroscience's Market Cap?

(NASDAQ: VIGL) Vigil Neuroscience's market cap is $112.83M, as of Feb 17, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vigil Neuroscience's market cap is calculated by multiplying VIGL's current stock price of $2.76 by VIGL's total outstanding shares of 40,879,485.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.